See What HealthDay Can Do For You
Contact Us

Omalizumab Protects Against Early, Late Allergic Responses

Significant reduction in early allergic reaction after 4 weeks, with decrease in FEV1, exhaled nitric oxide


THURSDAY, June 8, 2017 (HealthDay News) -- For patients with a significant response to allergen challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in Allergy.

Jordis Trischler, M.D., from the University Hospital Frankfurt in Germany, and colleagues determined the time course of the early (EAR) and late allergic reaction (LAR). Ten patients with a significant response to allergen challenge were treated with omalizumab. At week one, two, four, and eight, bronchial allergen provocations were repeated.

The researchers observed a significant reduction in EAR after four weeks (change in forced expiratory volume in one second [ΔFEV1], 28 versus 11 percent; P < 0.001; exhaled nitric oxide, 86 versus 53 ppb; P < 0.05), and there was a reduction in basophil activation after two weeks (CD63 expression, 79 versus 32 percent; P < 0.05). After one week there was a reduction in LAR (ΔFEV1, 26 versus 13 percent; P < 0.05).

"These results demonstrate the onset of protective effects earlier than previously determined, potentially improving seasonal utilization and combination with immunotherapy," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing